Fig. 3: PD-L1-CAR T cells inhibit the growth of human PD-L1high NSCLC in a xenograft model.
From: Targeting PD-L1 in non-small cell lung cancer using CAR T cells
a Experimental design of the tumor xenograft model infused with PD-L1-CAR or CD19-CAR T cells. b.NSG mice were inoculated with 1.0 × 106 H1975-Fluc cells and infused intravenously with 5 × 106 PD-L1-CAR T cells or CD19-CAR T cells twice on day 7 and 0 (n = 5 mice per group). Bioluminescence imaging was used to assess tumor growth on day 7, 14, and 28 post tumor cell inoculation. c Bioluminescence kinetics of H1975-Fluc (n = 5 mice per group). d The percentage of PD-L1-positive cells within tumors. All cells were extracted from tumors of each treatment group on day 28 after inoculation and the expression of PD-L1 was evaluated by flow cytometry. e Representative IHC images of CD19-CAR or PD-L1-CAR T cell-treated NSCLC tumors for PD-L1 and Ki67. Scale bars, 100 µm. f Hematoxylin and eosin staining of tumors or organs on day 28. Scale bars, 200 µm. ****p ≤ 0.0001.
